

## Special Issue

# Antibody-Drug Conjugates—a Coming of Age

### Message from the Guest Editor

Antibody-Drug Conjugates (ADCs) have finally come of age, with fifteen examples approved world-wide, seven by the FDA alone between 2019–2022. Furthermore, there are currently over 100 ADCs in clinical trials, with further approvals anticipated in the near future. In particular, ADCs such as trastuzumab deruxtecan-nxki (Enhertu®) have made a significant difference to the lives of cancer patients, as evidenced by clinical results recently announced at the 2022 ASCO conference (*i.e.*, reducing the risk of progression or death in HER2-low metastatic breast cancer by 49% vs. chemotherapy). To celebrate this success, we are pleased to invite you to submit manuscripts for a Special Issue of the journal *Cancers*, which will focus on cutting edge ADC research and development. In this Special Issue, both original research articles and reviews are welcome, and research areas may include (but are not limited to) targeting strategies, antibody/linker/payload design, and safety issues relating to ADCs. I look forward to receiving your contributions.

---

### Guest Editor

Prof. Dr. David E. Thurston

King's College London, Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, Franklin-Wilkins Building, London SE1 9NH, UK

---

### Deadline for manuscript submissions

closed (28 April 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/130354](https://mdpi.com/si/130354)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)